Thermo Fisher Scientific p27Kip1 (Mitotic Inhibitor/Suppressor Protein) Recombinant Rabbit Monoclonal Antibody (KIP1/1355R)

Applications

Immunohistochemistry (Paraffin) [IHC (P)]

• Tested Dilution: 1–2 µg/mL

Product Specifications

Product Specific Information

• Stability: Antibody is stable for 24 months.
• Positive Control: HeLa or MCF7 cells; human tonsil, breast, cervical, or colon carcinoma.
• Cellular Localization: Nuclear

Specificity Comments:
This monoclonal antibody recognizes a 27 kDa protein identified as p27Kip1, a cell cycle regulatory mitotic inhibitor. It is highly specific and shows no cross-reaction with other related mitotic inhibitors.
In Western blotting of lysates from seven human breast cancer cell lines (ZR75-1, ZR75-30, MCF-7, MDAMB453, T47D, CAL51, 734B), the antibody labels a single band corresponding to p27Kip1.
p27Kip1 is a candidate tumor suppressor gene. Low p27 expression has been associated with poor prognosis in renal cell carcinoma, colon carcinoma, breast carcinoma, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, and lymph node metastases in papillary thyroid carcinoma, as well as a more aggressive phenotype in cervical carcinoma.

Target Information

p27Kip1 functions as a negative regulator of G1 phase progression and may mediate TGF-β–induced G1 arrest. It is a potent inhibitor of cyclin E– and cyclin A–CDK2 complexes and participates in the assembly and regulation of cyclin D–CDK4 complexes.
Depending on its phosphorylation state and stoichiometry, p27Kip1 can act as either an inhibitor or activator of cyclin D–CDK4 complexes.
The protein (~27 kDa) undergoes degradation triggered by CDK-dependent phosphorylation and ubiquitination by SCF complexes, a process essential for the transition from quiescence to proliferation.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.